

Annals of Medicine and Surgery

Potential Anticancer Activity of Mn (II) Complexes Containing Arginine Dithiocarbamate Ligand on MCF-7 Breast Cancer Cell Lines --Manuscript Draft--

Manuscript Number:	AMSU-D-20-00466R1
Article Type:	Experimental Research
Keywords:	Arginine; Breast cancer; Complexes; Cytotoxic; MCF-7.
Corresponding Author:	Prihantono Prihantono, M.D. Universitas Hasanuddin Makassar, Sulawesi Selatan INDONESIA
First Author:	Prihantono Prihantono, M.D., Ph.D.
Order of Authors:	Prihantono Prihantono, M.D., Ph.D. Indah Raya, M.Si., PhD Rizal Irfandy, S.Si., M.Si Warsinggih Warsinggih, MD, PhD,
Manuscript Region of Origin:	INDONESIA
Abstract:	<p>Introduction : Cancers refer to genetic changes in the DNA structure accompanied by abnormal growth of normal cells, and resulting in the death of these structures, and is a disease currently recognized as a major cause of mortality globally. Chemotherapy plays important role in breast cancer management. Non-toxic metals have been developed to replace the highly toxic cisplatin, an example being Manganese. Furthermore, Ligands have displayed great capabilities in the determination of anticancer properties, and an essential agent exploited in drug development is arginine dithiocarbamate. Therefore, this study was conducted to examine the anticancer potentials of Mn (II) arginine dithiocarbamate.</p> <p>Methods : The synthesis and spectroscopic analysis of the Mn (II) Arginine dithiocarbamate complex was successfully carried out. Then, the complexes were characterized through the employment of the UV-Vis, FT-IR, as well as the melting point tests, and subsequently analyzed for anticancer activities through in vitro means. The compound was produced from UV-Vis spectrum at 246 and 385 nm wavelengths and IR spectrum at wave numbers 354-499 cm^{-1}.</p> <p>Results : The results revealed the cytotoxicity of Mn (II) Arginine dithiocarbamate against the MCF-7 cell line, observed from a significant change in the morphology of the cancer cells with IC50 value of 211.53 $\mu\text{g} / \text{mL}$.</p> <p>Conclusion : The compound, Mn (II) Arginine dithiocarbamate has effective anticancer potentials against MCF-7 cancer cells</p>
Response to Reviewers:	<p>Dear reviewer,</p> <p>Thank you for your valuable comment. Our replies to the reviewer's inquiries and revised points are as follows. Please confirm the relevant parts highlighted in yellow in the revised manuscript.</p> <p>1.Comment 1: Introduction How widely utilised is Mn(II) in combination with the ligand arginine dithiocarbamate in cancer therapy? Reply to comment 1: We have revised the introduction section. This stated on page 2 paragraph 2 and 3. Mn (II) metal is an essential metal which is widely used in the body as a cofactor in several enzymes.... The interaction of the Mn complex with DNA takes place through hydrogen bonds involving hydrogen bonds. ... The dithiocarbamate class of metal complexing compounds has become a new class of proteasome anticancer inhibitors with great potential to overcome the limitations seen with the use of bortezomib...</p> <p>2.Comment 2: Introduction Are there any complications or side effects associated with its use?</p>

Reply to comment 2:

We have revised the introduction section. This stated on page 3 paragraph 1.
... Complications from use are not yet known, because this is only stage 1 in vitro research, ...

3.Comment 3: Results and discussion

If would be helpful if the authors included in the discussion/conclusion what the key take away messages of this research are, and what has been learnt.

Reply to comment 3:

We have revised the discussion section. This stated on page 9.

Mn (II) metal complexes with arginine dithiocarbamate ligand have been successfully synthesized and characterized.

4.Comment 4: Results and discussion:

Please discuss the limitations and challenges encountered throughout this study, and how they were effectively overcome.

Reply to comment 4:

We have revised the discussion section. This stated on page 9.

The challenge faced in this study is the difficulty of finding a single solvent during the crystallization stage of the Mn complex, ...

We look forward to hearing from you

Best Regards,
Author

Annals of Medicine and Surgery

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

Please state any conflicts of interest

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

The authors declare that they have no conflict of interests.

Please state any sources of funding for your research

All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

No funding or sponsorship.

Ethical Approval

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement.

All procedure for human experiment has been approved by Ethics Commission
Faculty of Medicine, Hasanuddin University Number:
297/UN4.6.4.5.31/PP36/2019.

Consent

Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.

Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".

Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions.

Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

The research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. The patients have given their written informed consent on admission to use their prospective data base and files for research work.

Author contribution

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors.

PRI, RZI, IDR, and WS wrote the manuscript and participated in the study design. PRI, RZI, IDR, and WS drafted and revised the manuscript. PRI, RZI, and WS performed treatment and surgery. PRI, RZI, IDR, and WS performed bioinformatics analyses and revised the manuscript. All authors read and approved the final manuscript.

Registration of Research Studies

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.

You can register any type of research at <http://www.researchregistry.com> to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.

Not applicable

Guarantor

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish

Prihantono

COVER LETTER

September 7, 2020

Dear Editors,

I would like to submit the manuscript entitled “Potential Anticancer Activity of Mn (II) Complexes Containing Arginine Dithiocarbamate Ligand on MCF-7 Breast Cancer Cell Lines” by Prihantono to be considered for publication as an original research in Annals of Medicine and Surgery.

We found that the compound, Mn (II) Arginine dithiocarbamate has effective anticancer potentials against MCF-7 cancer cells. We believe these findings are relevant and will be of interest to the readers of your journal.

We declare that this manuscript is original, has not been published before and is not currently being considered for publication elsewhere.

We wish to confirm that there are no known conflicts of interest associated with this publication, and there has been no significant financial support for this work that could have influenced its outcome. As Corresponding Author, I confirm that the manuscript has been read and approved for submission by all the named authors.

We hope you find our manuscript suitable for publication and look forward to hearing from you in due course.

Sincerely,

Prihantono

Department of Surgery, Faculty of Medicine, Hasanuddin University Makassar, Indonesia
Jalan Perintis Kemerdekaan KM 11, Makassar, 90245, Indonesia

Fax: +62411585984

Email: prihantono.md@gmail.com

Dear reviewer,

Thank you for your valuable comment. Our replies to the reviewer's inquiries and revised points are as follows. Please confirm the relevant parts highlighted in yellow in the revised manuscript.

1. Comment 1: Introduction

How widely utilised is Mn(II) in combination with the ligand arginine dithiocarbamate in cancer therapy?

Reply to comment 1:

We have revised the introduction section. This stated on page 2 paragraph 2 and 3.

..... Mn (II) metal is an essential metal which is widely used in the body as a cofactor in several enzymes.... The interaction of the Mn complex with DNA takes place through hydrogen bonds involving hydrogen bonds.

... The dithiocarbamate class of metal complexing compounds has become a new class of proteasome anticancer inhibitors with great potential to overcome the limitations seen with the use of bortezomib...

2. Comment 2: Introduction

Are there any complications or side effects associated with its use?

Reply to comment 2:

We have revised the introduction section. This stated on page 3 paragraph 1.

... Complications from use are not yet known, because this is only stage 1 in vitro research, ...

3. Comment 3: Results and discussion

If would be helpful if the authors included in the discussion/conclusion what the key take away messages of this research are, and what has been learnt.

Reply to comment 3:

We have revised the discussion section. This stated on page 9.

Mn (II) metal complexes with arginine dithiocarbamate ligand have been successfully synthesized and characterized.

4. Comment 4: Results and discussion:

Please discuss the limitations and challenges encountered throughout this study, and how they were effectively overcome.

Reply to comment 4:

We have revised the discussion section. This stated on page 9.

The challenge faced in this study is the difficulty of finding a single solvent during the crystallization stage of the Mn complex, ...

We look forward to hearing from you

Best Regards,

Author

Highlights

- Chemotherapy plays important role in breast cancer management.
- Non-toxic metals have been developed to replace the highly toxic cisplatin, an example being Manganese (Mn).
- The compound, Mn (II) Arginine dithiocarbamate has effective anticancer potentials against MCF-7 cancer cells.

Potential Anticancer Activity of Mn (II) Complexes Containing Arginine Dithiocarbamate Ligand on MCF-7 Breast Cancer Cell Lines

Prihantono¹, Rizal Irfandy², Indah Raya³, Warsinggih¹

¹Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

²Department of Biology Education, Faculty of Teacher Training and Education, Universitas Puangrimaggalatung, Sengkang, Indonesia.

³Department of Chemistry, Faculty of Mathematic, and Natural Science, Hasanuddin University, Makassar, Indonesia

Name Author	Email	ORCID ID
1. Prihantono	prihantono.md@gmail.com	0000-0002-8247-0457
2. Rizal Irfandy	rizalirfandi043@gmail.com	
3. Indah Raya	indahraya05@gmail.com	
4. Warsinggih	kbd.warsinggih@gmail.com	0000-0002-1756-9039

Corresponding author:

Prihantono

Department of Surgery, Faculty of Medicine, Hasanuddin University Makassar, Indonesia
Jalan Perintis Kemerdekaan KM 11, Makassar, 90245, Indonesia

Fax: +62411585984

Email: prihantono.md@gmail.com

Acknowledgment

A higher appreciation to all staff from the Inorganic Research Center Laboratory of Hasanuddin University, Makassar, Indonesia.

Potential Anticancer Activity of Mn (II) Complexes Containing Arginine Dithiocarbamate Ligand on MCF-7 Breast Cancer Cell Lines

ABSTRACT

Introduction: Cancers refer to genetic changes in the DNA structure accompanied by abnormal growth of normal cells, and resulting in the death of these structures, and is a disease currently recognized as a major cause of mortality globally. Chemotherapy plays important role in breast cancer management. Non-toxic metals have been developed to replace the highly toxic cisplatin, an example being Manganese. Furthermore, Ligands have displayed great capabilities in the determination of anticancer properties, and an essential agent exploited in drug development is arginine dithiocarbamate. Therefore, this study was conducted to examine the anticancer potentials of Mn (II) arginine dithiocarbamate.

Methods: The synthesis and spectroscopic analysis of the Mn (II) Arginine dithiocarbamate complex was successfully carried out. Then, the complexes were characterized through the employment of the UV-Vis, FT-IR, as well as the melting point tests, and subsequently analyzed for anticancer activities through in vitro means. The compound was produced from UV-Vis spectrum at 246 and 385 nm wavelengths and IR spectrum at wave numbers 354-499 cm^{-1} .

Results: The results revealed the cytotoxicity of Mn (II) Arginine dithiocarbamate against the MCF-7 cell line, observed from a significant change in the morphology of the cancer cells with IC₅₀ value of 211.53 $\mu\text{g} / \text{mL}$.

Conclusion: The compound, Mn (II) Arginine dithiocarbamate has effective anticancer potentials against MCF-7 cancer cells

Keywords: Arginine; Breast Cancer; Complexes; Cytotoxic; MCF-7.

INTRODUCTION

Cancer occurs as a result of changes in DNA resulting in uncontrolled cell growth [1,2]. This disease became the second leading cause of death globally in 2015 [3], with breast cancer presenting with the highest incidence in Indonesia in 2013 at a prevalence of 0.5%, according to the data compiled by the 2013 Basic Health Research. Also, this form of cancer generates the highest number of new cases, based on the data provided by Dharmais Cancer Hospital for four years, with 819 patients and 217 deaths, and these figures are on a continuous rise [4].

Consequently, the interaction of metal complexes with DNA has attracted abundant attention in research world, and similar to the application in medicine, photodynamic therapy (PDT) is a cancer healing method with favorable prospects [5]. Mn (II) metal is an essential metal which is widely used in the body as a cofactor in several enzymes [6]. Arginine is an amino acid that is needed by the body to run metabolism [7]. Dithiocarbamate also in the body has less toxicity [8]. These three reasons make the use of Mn (II) in combination with the arginine thiocarbamate ligand in cancer therapy to have very less side effects or complications. Coordination of Mn (II) with emodin can increase anticancer activity. The complex can cause changes in cell morphology, reduce the percentage of viability, and induce G0 / G1 phase capture and apoptosis in cancer cells [9]. Based on UV-Vis and IR spectroscopic studies that Mn (II), forms complexes with DNA. The interaction of the Mn complex with DNA takes place through hydrogen bonds involving hydrogen bonds [10].

Dithiocarbamate is a uniquely structured compound, owing to the presence of S group as both a monodentate and bidentate electron donor. These compounds bond predominantly with transition metals to form complexes, an example seen with manganese metals [11–13]. Meanwhile, the use of these ligands with arginine as an additional donor increases the diversity of the complex structure, and also influences the biological activity [14]. The dithiocarbamate class of metal complexing compounds has become a new class of proteasome anticancer inhibitors with great potential to overcome the limitations seen with the use of bortezomib [15]. Dithiocarbamates are a class of metal chelating compounds with various applications in medicine. Dithiocarbamate has been used for the treatment of bacterial and fungal infections, possibly the treatment of AIDS, and most recently cancer. Chemotherapy agents are currently highly toxic and therefore their efficacy in eradicating tumors is very limited. As a result many scientists have joined in the search for new targeted therapies with the hope of reducing toxicity while maximizing their potency and proteasome

inhibition has become an interesting therapy in this regard. Here we discuss the origin, mechanism, and evolution of dithiocarbamates as potent proteasome inhibitors and therefore anti-cancer agents [15,16]. Coordination based on dithiocarbamate compounds as a potent proteasome inhibitor in human cancer cells. Thus, this approach could pave the way for the development of nontoxic anticancer therapies [16].

Complications from use are not yet known, because this is only stage 1 in vitro research, then stage 2 research will be carried out in animals, and finally stage 3 in humans. Mn (II) arginine dithiocarbamate complex is predicted to have low side effects when compared to cisplatin because the metal raw material used in this study is an essential metal and has biological activity in the body. For this reason, this study uses the generally environmentally-friendly and minimally toxic Mn (II), in combination with the ligand arginine dithiocarbamate, as potential candidates in tumor/cancer therapy. Furthermore, biologically active complexes have garnered extensive attention as inclusions in the design of potential antitumor agents [17]. Also, dithiocarbamate ligands are known to be medically beneficial, and are utilized as radio target in the chemotherapy of tumors [18,19].

Therefore, this research aims to characterize the synthesized Mn (II) arginine dithiocarbamate complex and examine the compound's anticancer activity against MCF-7 cell line, and the analysis outcomes were determinants of the compound's anticancer efficacy.

METHODS

Materials

CS₂ 99.5% (Ajax Chemical Ltd), Cisplatin, Roswell Park Memorial Institute Medium, DMSO, Manganese(II)sulphate, cysteine PA, 95% Ethanol, 95% methanol, 95% Acetone, 95% n-hexane, and 95% Acetonitrile (Central Laboratory of Hasanuddin University, Indonesia). MCF-7 were tested at Padjadjaran University.

Synthesis of Mn (II) Complex Compounds with arginine dithiocarbamate ligand

A mass of 0.5095g MnSO₄.H₂O (3mmol) was placed in an Erlenmeyer glass, and made into a solution with 10 mL of ethyl alcohol (solution 1), accompanied by 0.9001g (5mmol) of Arginine, and a subsequent dissolution with 10 mL of ethanol. Then, 0.302 mL (5mmol) CS₂ solution was added to solution 1 slowly at cold temperature, and combined with a magnetic stirrer for 30 minutes (solution 2). Additionally, the resulting precipitate

was filtered and placed in a desiccator to facilitate dehydration, and then crystallized with a solvent prepared from an acetonitrile and ethanol blend (1: 2, v / v), to obtain pure crystals to be further analyzed and characterized.

Characterization of Mn (II) Arginine dithiocarbamate Complexes

The ligands were physically characterized by the implementation of melting point and conductivity tests, as well as chemically by UV-Vis and FT-IR spectrophotometric assays.

Cytotoxicity Test against Cancer Cell Lines

The sample solutions of the complexes at various concentrations, alongside cisplatin ($IC_{50} = 5.7 \mu\text{g} / \text{mL}$) used as a positive control were added to the MCF-7 cells and subsequently incubated for 24 hours. Then, the resulting mixture was added to the dye reagent and re-incubated for another 4 hours at 37 °C. Consequently, the number of HeLa cells inhibited by the test sample after uptake was measured by the use of a multimode reader at λ_{maks} (570-600 nm) after the inclusion of stop solution reagents. Furthermore, the IC_{50} values were calculated by the extrapolation of the 50% line produced by the uptake of the positive control on the absorption curve at various sample concentrations.

Preparation of Media, Positive Control and Arginine dithiocarbamate complex

The liquid culture media was prepared at the Roswell Park Memorial Institute Medium (RPMI) by the combination of 10% Fetal Bovine Serum (FBS) and 50 μL /50mL antibiotics, with Cisplatin as the positive control. Meanwhile, the stock was prepared by the dissolution of cysteine dithiocarbamate complex in the nontoxic solvent, DMSO at a series of strengths. Furthermore, the antiproliferation assay work solution used was the Presto Blue™ Cell Viability Reagent.

Preparation of MCF-7 Cells

The MCF-7 cells were confluent at 70%, discharged onto media dish, and doused with 1 mL *Phosphate Buffered Saline* (PBS) two times, followed by 1 ml Trypsin-EDTA solution added into the dish, and then incubated for 5 minutes. Furthermore, the cell layers were dispersed, and appeared to float when viewed with the inverted microscope. Finally, the cells were inserted into a tube containing growth media, rotated at 3000 rpm for 5 minutes, the supernatant subsequently disposed, and the resultant pellets dissolved in a tube

of media.

Seeding cells into 96 well plates

The cell count and viability were performed with trypan blue exclusion, and then resuspended to produce a final density of 170,000 cells/mL in the media. (17,000 cells/well). Meanwhile, 10 μ L of trypan blue was prepared in sterile microtube, 10 μ L of the cell suspension added to the solution and subsequently homogenized. Then, the hemocytometers and the lids were cleaned with the use of 70% ethanol, dried, and 10 μ L of the trypan blue cell solution inserted slowly into one of the chambers with the use of a pipette. Finally, the number of viable cells per mL was determined, the cell cultures seeded into 96 well plates, incubated for 24 hours or until a minimum of 70% confluent cells at 37°C and 5% CO₂ gas were observed.

Cell treatment with positive sample/ positive control/negative control

A total of eight 1.5 mL microtubes were prepared, with each container labeled with the appropriate dilution strength, and the sample stock diluted into eight corresponding concentration variants with the use of a media solvent. Then, 96 well plates containing cells from the incubator were collected and labelled along the left margins according to the rows to be treated by the standard or sample. In addition, the media was discarded from each well. Then, 100 μ L of each sample, along with the cisplatin control in the microtubes were transferred into each of the corresponding wells on the 96 plates containing the cells with the use of a micropipette and subsequently re-incubated for 24 hours.

Provision of Presto Blue reagents and absorbance measurements

A volume of 9 mL of media from each tube was added to 1mL of "Presto Blue™ Cell Viability Reagent" (10 μ L of reagent for 90 μ L media), and then 100 μ L of the resulting mixture inserted into each well. After this, the microplates were incubated for 1-2 hours until discoloration occurred. On entrance into the viable cell, the indicator was transformed from the non-luminous resazurin blue, into the highly fluorescent resorufin counterpart. The converted values were proportionate to the living cell count, and the absorbances were consequently capable of quantitative measurement, as the absorbance spectrum was utilized for resazurin and resorufin. Finally, these values were estimated at a wave length of 570nm (reference: 600nm) using a multimode reader.

RESULTS

The yield of the Mn(II) arginine dithiocarbamate compound synthesized was 28.39%, and the melting point estimated between 202°C – 204°C.

UV-Vis characterization

The complex characterized by UV-Vis spectrophotometers displayed several wavelengths as illustrated in Table 1. Furthermore, the absorption at 385 nm was representative of the transition of electrons from the orbital $n \rightarrow \pi^*$ in the group $N = C = S$. Meanwhile, the wavelength of 246 nm indicated a transition from the orbitals $\pi \rightarrow \pi^*$ in the group CS_2 , attributable to the hyperconjugation effect experienced by the R group. The spectral outcomes of the synthesized ligand are shown in figure 2.

IR characterization

A single bond group ν (C - N) exists in the dithiocarbamate complex at the wave number between 1350-1250 cm^{-1} and ν (C = N) at 1690 - 1640 cm^{-1} . Meanwhile, the C - S bond group occurs at wave numbers 550 – 800 cm^{-1} , and the C = S at 1050-1200 cm^{-1} [11]. Furthermore, the bonds between the metal and the ligands are observable from the far infrared absorption ranging from the wave number 400-100 cm^{-1} , as seen in the linkages formed between sulfur or nitrogen and metals [12].

Also, the metal coordination bonds with ligands are identifiable from the resulting spectrum as observed in Table 2. Subsequently, the interactions between the Mn bond and the S group were detected at wave number 354 cm^{-1} , with the O atom at 445 cm^{-1} and finally, the N atom at 499 cm^{-1} . In addition, the C = N double bond was identified from the spectrum with the wave number 1645 cm^{-1} , while the C = S double bond coordinating with Mn ion was observed at 1116 cm^{-1} . Furthermore, Figure 3 shows the FT-IR spectrum of the complex compound, with each compound having a specific absorption in the infrared spectrum dependent on the metal and ligands.

Cytotoxicity Test on MCF-7 Cells

The IC_{50} value of the complex was determined from the regression equation $y = -0.0016x + 0.6826$ (Figure 4), obtained by replacing the value of y with half the value of the control (DMSO). Subsequently, the well plate documentation results of Mn (II) arginine dithiocarbamate, as well as the comparison of sample concentrations with media + cells, alongside cisplatin for MCF-7 are displayed in Figure 5. Also, the IC_{50} of the sample were

evaluated due to similarities of the color to cisplatin, and the value obtained between 125-250 $\mu\text{g} / \text{mL}$.

The apoptosis of MCF-7 cells against cisplatin and a sample of the complex are illustrated in Figure 6, and this phase was dependent on the concentration and nature of the inhibitory substance. Subsequently, in the concentration of the sample variant from 7.81 to 62.5 $\mu\text{g} / \text{mL}$, no visible cell death was observed, and this phenomenon was capable of associated to the image of the initial cell media that remained normal without treatment. Therefore, apoptosis commenced at the 125 $\mu\text{g}/\text{mL}$ concentration sample, after an addition of cisplatin to the media. Also, the MCF-7 cells experienced late apoptosis at higher concentrations.

Discussion

Metals exhibit distinct features comprising redox activity, several coordination structures, and reactivity towards organic compounds. As a result of this function, these elements typically undergo strict regulations, and abnormal ionic strengths are affiliated with numerous diseases, including cancer [13]. Therefore, metal complexes, either as drugs or prodrugs, have become very promising anticancer candidates [14,20,21]. Also, the use of metals and the corresponding salts for medicinal purposes, from iatrochemistry to contemporary medicine, has existed from time immemorial [21,22]. Consequently, the invention of cisplatin, $\text{cis-}[\text{Pt}(\text{II})(\text{NH}_3)_2\text{Cl}_2]$, was a breakthrough and sparked interests in platinum(II)- and other metallic composites as prospective chemotherapeutic agents [13].

Moreover, transition metals including copper, iron, and manganese, and so on, are linked with many biological processes, including electron transfer and catalysis, as well as fundamental functions, and are therefore regularly involved with the binding sites of biological polypeptides [23,24]. Manganese (Mn) is an essential trace metal indispensable in enzyme functionality, for instance, arginase, glutamine synthetase, and Mn-superoxide dismutase activity [25]. Furthermore, this metal is able to assume various valence forms, and limited data suggest the propensity to undergo oxidative modifications whilst in the body [26,27]. Despite the normal oxidation number of the ion in enzymes being Mn(III), majority of manganese intake from diet and other circumstances are either Mn(II) or Mn(IV) [27]. This metal is principal for the maintenance of the functionality, as well as

biochemical and cellular modulation required by living organisms [28]. Also, the element is vital for growth and development, acts during the activation of immunity, blood glucose control, adenosine triphosphate (ATP) regulation, reproduction, digestion and skeletal growth [28,29].

In addition to tetraethylthiuram disulfide (DSF), diethyldithiocarbamate (DDTC) and pyrrolidine dithiocarbamate (PDTC) also belong to the dithiocarbamate group revealed as powerful metal sequestering agents [13,30–33]. DDTC was revealed to be capable of combining with copper to create a novel potent inhibitory complex of functions similar to proteasomal chymotrypsin, promote cell death, decrease androgen (AR) and estrogen receptor (ER α and ER β) protein manifestation in malignant prostate and breast tissues [13]. Reports garnered further revealed PDTC, after linkage to copper, exhibited comparable activities on cultivated human prostate cancer cells, along with the suppression of proliferation [33]. Also, the anticancer activity of copper has been postulated to reflect in the manganese (II) arginine dithiocarbamate compound.

The cytotoxicity of the synthesized complex was tested in vitro against the MCF-7 cancer cells and compared with cisplatin, the most commonly used drug currently recognized as toxic to these cancer cells. From the results displayed on Table 3, the IC₅₀ value of the Mn (II) complex was similar to the value of cisplatin, and hence, expressed as active against cancer cells. Furthermore, the cytotoxicity results of the complex were more effective against the cells (IC₅₀ = 211.53 $\mu\text{g} / \text{mL}$) when compared to the IC₅₀ value of 632.42 $\mu\text{g} / \text{mL}$ produced by the semi-polar fraction of *Dioscorea esculenta* L. as reported by Haryoto [34].

According to the Prayong classification (2008) [35] regarding the IC₅₀ standard for cytotoxic samples, the Mn (II) complex belongs to the medium cytotoxic category owing as the IC₅₀ value occurred between 100-1000 $\mu\text{g}/\text{mL}$. In addition, the ligand's cytotoxic activities against the cell line are perceivable in terms of the bioactivity of metals in the body, as well as the complex structural properties. Also, the consideration of Mn (II) from the view of HSAB properties included in the category of borderline acids and Nitrogen groups from guanine, the basic framework of DNA included in the category of soft bases, permitted the formation of a strong bond between the complex and two DNA strands in a double helix. Furthermore, the nature of Mn, an essential element with bioactive capacities in the human body, compared to harmful cisplatin, depleted the toxicity. Subsequently, the high IC₅₀ value of the Mn(II) complex was influenced by arginine dithiocarbamate ligands employed in the synthesis of complex compounds, and able to process ligand intercalation

into DNA base pairs. Therefore, the propensity of metal complexes to not only covalently coordinate, but also bond non-covalently was affirmed, and this ion was able to interact with DNA through the formation of intra-strand cross-links [36]. Also, the resulting bonds prevented the mitotic phase of cancer cells, causing these structures to become stiff, deter repair and induce cellular apoptosis.

Mn (II) metal complexes with arginine dithiocarbamate ligand have been successfully synthesized and characterized. And it shows that there has been coordination between the Mn (II) atom with Sulfur (S), Nitrogen (N) and Oxygen (O) from the arginine dithiocarbamate ligand. This complex can inhibit cancer cell proliferation in a way that depends on the concentration of the Mn (II) complex. Its IC₅₀ value indicates that Mn (II) arginine dithiocarbamate has excellent inhibitory activity against MCF-7 cancer cells. In fact, the Mn (II) arginine dithiocarbamate complex can make cancer cells undergo apoptosis in vitro in a concentration-dependent way, which can inhibit the proliferation of MCF-7 cancer cells [9]. Thus, the Mn (II) arginine dithiocarbamate complex could be a potential cancer drug.

The challenge faced in this study is the difficulty of finding a single solvent during the crystallization stage of the Mn complex, as for the solution by using a double solvent, namely acetonitrile and ethanol.

Conclusions

The Mn (II) arginine dithiocarbamate complex synthesis was performed by an in-situ method through an interaction between a primary amine (arginine) and carbon disulfide (CS₂) in ethanol, alongside the Mn metal solvents in the form of salts. In addition, the analysis of the Mn (II) complex against MCF-7 cancer cell line revealed the existence of moderate cytotoxicity with IC₅₀ = 211.53 µg / mL, attesting to activity as opposed to the cell line.

References

- [1] A. Adjiri, DNA Mutations May Not Be the Cause of Cancer, *Oncol. Ther.* 5 (2017) 85–101. <https://doi.org/10.1007/s40487-017-0047-1>.
- [2] M.R. Stratton, P.J. Campbell, P.A. Futreal, The cancer genome, *Nature.* 458 (2009) 719–724. <https://doi.org/10.1038/nature07943>.
- [3] J. Ferlay, I. Soerjomataram, M. Ervik, R. Dikshit, S. Eser..., *Cancer Incidence and*

- Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013, (2015).
- [4] M. of H.R. of Indonesia, Panduan Program Nasional Gerakan Pencegahan dan Deteksi Dini Kanker Leher Rahim dan Kanker Payudara, (2015). <http://www.depkes.go.id/article/view/15021800011/situasi%20penyakit%20kanker.html>.
- [5] B.W. Henderson, T.J. Dougherty, HOW DOES PHOTODYNAMIC THERAPY WORK?, *Photochem. Photobiol.* 55 (1992) 145–157. <https://doi.org/10.1111/j.1751-1097.1992.tb04222.x>.
- [6] M.A. Zoroddu, J. Aaseth, G. Crisponi, S. Medici, M. Peana, V.M. Nurchi, The essential metals for humans: a brief overview, *J. Inorg. Biochem.* 195 (2019) 120–129. <https://doi.org/10.1016/j.jinorgbio.2019.03.013>.
- [7] S.M. Morris, Arginine Metabolism Revisited, *J. Nutr.* 146 (2016) 2579S-2586S. <https://doi.org/10.3945/jn.115.226621>.
- [8] A. Royer, M. Ménand, A. Grimault, P.Y. Communal, Development of Automated Headspace Gas Chromatography Determination of Dithiocarbamates in Plant Matrixes, *J. Agric. Food Chem.* 49 (2001) 2152–2158. <https://doi.org/10.1021/jf0013196>.
- [9] L. YANG, J. TAN, B.-C. WANG, L.-C. ZHU, Synthesis, characterization, and anti-cancer activity of emodin-Mn(II) metal complex, *Chin. J. Nat. Med.* 12 (2014) 937–942. [https://doi.org/10.1016/S1875-5364\(14\)60137-0](https://doi.org/10.1016/S1875-5364(14)60137-0).
- [10] E. Sletten, N. ge Frystein, Sequence-Selective Binding of Transition Metal Complexes to DNA, in: N. Hadjiliadis, E. Sletten (Eds.), *Met. Complex–DNA Interact.*, John Wiley & Sons, Ltd, Chichester, UK, 2009: pp. 1–30. <https://doi.org/10.1002/9781444312089.ch1>.
- [11] C. Bernal, E.A. Neves, É.T.G. Cavalheiro, Differences in thermal decomposition of Ag (I), Mn (II), Fe (II) and Fe (III) complexes of cyclic dithiocarbamates, *Thermochim. Acta.* 370 (2001) 49–55.
- [12] B. Wang, H.-Z. Ma, Q.-Z. Shi, Chiral lanthanide(III) complexes of sulphur–nitrogen–oxygen ligand derived from aminothiourea and sodium D-camphor- β -sulfonate, *Inorg. Chem. Commun.* 4 (2001) 409–412. [https://doi.org/https://doi.org/10.1016/S1387-7003\(01\)00223-4](https://doi.org/https://doi.org/10.1016/S1387-7003(01)00223-4).
- [13] M. Frezza, S. Hindo, D. Chen, A. Davenport, S. Schmitt, D. Tomco, Q.P. Dou, Novel metals and metal complexes as platforms for cancer therapy., *Curr. Pharm. Des.* 16 (2010) 1813–1825. <https://doi.org/10.2174/138161210791209009>.

- [14] M. Galanski, Recent developments in the field of anticancer platinum complexes., *Recent Pat. Anticancer. Drug Discov.* 1 (2006) 285–295. <https://doi.org/10.2174/157489206777442287>.
- [15] M. Frezza, S. Schmitt, Q. Ping Dou, Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy, *Curr. Top. Med. Chem.* 11 (2011) 2888–2905. <https://doi.org/10.2174/156802611798281311>.
- [16] D. Buac, S. Schmitt, G. Ventro, F. Rani Kona, Q. Ping Dou, Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells, *Mini-Reviews Med. Chem.* 12 (2012) 1193–1201. <https://doi.org/10.2174/138955712802762040>.
- [17] N. Awang, I. Baba, Diorganotin(IV) Alkylcyclohexyldithiocarbamate Compounds: Synthesis, Characterization and Biological Activities (Sebatian Diorganostanum(IV) Alkilsikloheksilditiokarbamat: Sintesis, Pencirian dan Aktiviti Biologi), in: 2008.
- [18] A. Korde, D. Satpati, A. Mathur, M. Mallia, S. Banerjee, K. Kothari, H.D. Sarma, P. Choudhari, M. Venkatesh, ^{99m}Tc-labeling of colchicine using [^{99m}Tc(CO)₃(H₂O)₃]⁺ and [^{99m}TcN]₂⁺ core for the preparation of potential tumor-targeting agents, *Bioorg. Med. Chem.* 14 (2006) 793–799. <https://doi.org/10.1016/j.bmc.2005.09.006>.
- [19] I. Baba, I. Raya, Praseodymium Dithiocarbamate 1,10 Phenantroline Complexes, *Sains Malaysiana.* 39 (2010) 45–50.
- [20] V. Milacic, D. Fregona, Q.P. Dou, Gold complexes as prospective metal-based anticancer drugs., *Histol. Histopathol.* 23 (2008) 101–108. <https://doi.org/10.14670/HH-23.101>.
- [21] L.R. Kelland, An update on satraplatin: the first orally available platinum anticancer drug, *Expert Opin. Investig. Drugs.* 9 (2000) 1373–1382. <https://doi.org/10.1517/13543784.9.6.1373>.
- [22] D. Wang, S. Lippard, Cellular processing of platinum anticancer drugs, *Nat. Rev. Drug Discov.* 4 (2005) 307–320.
- [23] C. Orvig, M.J. Abrams, Medicinal Inorganic Chemistry: Introduction, *Chem. Rev.* 99 (1999) 2201–2204. <https://doi.org/10.1021/cr980419w>.
- [24] S.S. Hindo, M. Frezza, D. Tomco, M.J. Heeg, L. Hryhorczuk, B.R. McGarvey, Q.P. Dou, C.N. Verani, Metals in anticancer therapy: Copper(II) complexes as inhibitors of the 20S proteasome, *Eur. J. Med. Chem.* 44 (2009) 4353–4361. <https://doi.org/https://doi.org/10.1016/j.ejmech.2009.05.019>.

- [25] D.S. Ávila, L.G. Costa, M. Aschner, Manganese, in: M.J. Aminoff, R.B.B.T.-E. of the N.S. (Second E. Daroff (Eds.)), *Encycl. Neurol. Sci.*, Second Edi, Academic Press, Oxford, 2014: pp. 995–997. <https://doi.org/https://doi.org/10.1016/B978-0-12-385157-4.00263-3>.
- [26] M. ŠARIĆ, R. LUCCHINI, Manganese, in: G.F. Nordberg, B.A. Fowler, M. Nordberg, L.T.B.T.-H. on the T. of M. (Third E. Friberg (Eds.)), *Handb. Toxicol. Met.*, Third Edit, Academic Press, Burlington, 2007: pp. 645–674. <https://doi.org/https://doi.org/10.1016/B978-012369413-3/50087-2>.
- [27] R.G. Lucchini, M. Aschner, Yangho kim, M. Šarić, Manganese, in: G.F. Nordberg, B.A. Fowler, M.B.T.-H. on the T. of M. (Fourth E. Nordberg (Eds.)), *Handb. Toxicol. Met.*, Fourth Edi, Academic Press, San Diego, 2015: pp. 975–1011. <https://doi.org/https://doi.org/10.1016/B978-0-444-59453-2.00045-7>.
- [28] D. Milatovic, R.C. Gupta, Z. Yin, S. Zaja-Milatovic, M. Aschner, Manganese, in: R.C.B.T.-R. and D.T. (Second E. Gupta (Ed.)), *Reprod. Dev. Toxicol.*, Second, Academic Press, 2017: pp. 567–581. <https://doi.org/https://doi.org/10.1016/B978-0-12-804239-7.00032-9>.
- [29] D. Milatovic, R.C. Gupta, Z. Yin, S. Zaja-Milatovic, M. Aschner, Manganese, in: R.C.B.T.-R. and D.T. Gupta (Ed.), *Reprod. Dev. Toxicol.*, First, Academic Press, San Diego, 2011: pp. 439–450. <https://doi.org/https://doi.org/10.1016/B978-0-12-382032-7.10034-7>.
- [30] D. Chen, V. Milacic, M. Frezza, Q.P. Dou, Metal complexes, their cellular targets and potential for cancer therapy., *Curr. Pharm. Des.* 15 (2009) 777–791. <https://doi.org/10.2174/138161209787582183>.
- [31] V. Milacic, D. Chen, L. Giovagnini, A. Diez, D. Fregona, Q.P. Dou, Pyrrolidine dithiocarbamate-zinc(II) and -copper(II) complexes induce apoptosis in tumor cells by inhibiting the proteasomal activity, *Toxicol. Appl. Pharmacol.* 231 (2008) 24–33. <https://doi.org/https://doi.org/10.1016/j.taap.2008.03.009>.
- [32] D. Chen, Q.P. Dou, New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer, *Expert Opin. Ther. Targets.* 12 (2008) 739–748. <https://doi.org/10.1517/14728222.12.6.739>.
- [33] D. Chen, F. Peng, Q.C. Cui, K.G. Daniel, S. Orlu, J. Liu, Q.P. Dou, Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis., *Front. Biosci.* 10 (2005) 2932–2939. <https://doi.org/10.2741/1749>.

- [34] H. Haryoto, Cytotoxic Activities of Ethanol Extract, Nonpolar Semipolar, and Polar Fractions of *Dioscorea esculenta* L.) on MCF7 Cancer Cell, *J. Nutraceuticals Herb. Med.* 2 (2019) 12–19.
- [35] P. Prayong, S. Barusrux, N. Weerapreeyakul, Cytotoxic activity screening of some indigenous Thai plants., *Fitoterapia.* 79 (2008) 598–601. <https://doi.org/10.1016/j.fitote.2008.06.007>.
- [36] R.A. Alderden, M.D. Hall, T.W. Hambley, The Discovery and Development of Cisplatin, *J. Chem. Educ.* 83 (2006) 728. <https://doi.org/10.1021/ed083p728>.

Potential Anticancer Activity of Mn (II) Complexes Containing Arginine Dithiocarbamate Ligand on MCF-7 Breast Cancer Cell Lines

ABSTRACT

Introduction: Cancers refer to genetic changes in the DNA structure accompanied by abnormal growth of normal cells, and resulting in the death of these structures, and is a disease currently recognized as a major cause of mortality globally. Chemotherapy plays important role in breast cancer management. Non-toxic metals have been developed to replace the highly toxic cisplatin, an example being Manganese. Furthermore, Ligands have displayed great capabilities in the determination of anticancer properties, and an essential agent exploited in drug development is arginine dithiocarbamate. Therefore, this study was conducted to examine the anticancer potentials of Mn (II) arginine dithiocarbamate.

Methods: The synthesis and spectroscopic analysis of the Mn (II) Arginine dithiocarbamate complex was successfully carried out. Then, the complexes were characterized through the employment of the UV-Vis, FT-IR, as well as the melting point tests, and subsequently analyzed for anticancer activities through in vitro means. The compound was produced from UV-Vis spectrum at 246 and 385 nm wavelengths and IR spectrum at wave numbers 354-499 cm^{-1} .

Results: The results revealed the cytotoxicity of Mn (II) Arginine dithiocarbamate against the MCF-7 cell line, observed from a significant change in the morphology of the cancer cells with IC₅₀ value of 211.53 $\mu\text{g} / \text{mL}$.

Conclusion: The compound, Mn (II) Arginine dithiocarbamate has effective anticancer potentials against MCF-7 cancer cells

Keywords: Arginine; Breast Cancer; Complexes; Cytotoxic; MCF-7.

INTRODUCTION

Cancer occurs as a result of changes in DNA resulting in uncontrolled cell growth [1,2]. This disease became the second leading cause of death globally in 2015 [3], with breast cancer presenting with the highest incidence in Indonesia in 2013 at a prevalence of 0.5%, according to the data compiled by the 2013 Basic Health Research. Also, this form of cancer generates the highest number of new cases, based on the data provided by Dharmais Cancer Hospital for four years, with 819 patients and 217 deaths, and these figures are on a continuous rise [4].

Consequently, the interaction of metal complexes with DNA has attracted abundant attention in research world, and similar to the application in medicine, photodynamic therapy (PDT) is a cancer healing method with favorable prospects [5]. Mn (II) metal is an essential metal which is widely used in the body as a cofactor in several enzymes [6]. Arginine is an amino acid that is needed by the body to run metabolism [7]. Dithiocarbamate also in the body has less toxicity [8]. These three reasons make the use of Mn (II) in combination with the arginine thiocarbamate ligand in cancer therapy to have very less side effects or complications. Coordination of Mn (II) with emodin can increase anticancer activity. The complex can cause changes in cell morphology, reduce the percentage of viability, and induce G0 / G1 phase capture and apoptosis in cancer cells [9]. Based on UV-Vis and IR spectroscopic studies that Mn (II), forms complexes with DNA. The interaction of the Mn complex with DNA takes place through hydrogen bonds involving hydrogen bonds [10].

Dithiocarbamate is a uniquely structured compound, owing to the presence of S group as both a monodentate and bidentate electron donor. These compounds bond predominantly with transition metals to form complexes, an example seen with manganese metals [11–13]. Meanwhile, the use of these ligands with arginine as an additional donor increases the diversity of the complex structure, and also influences the biological activity [14]. The dithiocarbamate class of metal complexing compounds has become a new class of proteasome anticancer inhibitors with great potential to overcome the limitations seen with the use of bortezomib [15]. Dithiocarbamates are a class of metal chelating compounds with various applications in medicine. Dithiocarbamate has been used for the treatment of bacterial and fungal infections, possibly the treatment of AIDS, and most recently cancer. Chemotherapy agents are currently highly toxic and therefore their efficacy in eradicating tumors is very limited. As a result many scientists have joined in the search for new targeted therapies with the hope of reducing toxicity while maximizing their potency and proteasome

inhibition has become an interesting therapy in this regard. Here we discuss the origin, mechanism, and evolution of dithiocarbamates as potent proteasome inhibitors and therefore anti-cancer agents [15,16]. Coordination based on dithiocarbamate compounds as a potent proteasome inhibitor in human cancer cells. Thus, this approach could pave the way for the development of nontoxic anticancer therapies [16].

Complications from use are not yet known, because this is only stage 1 in vitro research, then stage 2 research will be carried out in animals, and finally stage 3 in humans. Mn (II) arginine dithiocarbamate complex is predicted to have low side effects when compared to cisplatin because the metal raw material used in this study is an essential metal and has biological activity in the body. For this reason, this study uses the generally environmentally-friendly and minimally toxic Mn (II), in combination with the ligand arginine dithiocarbamate, as potential candidates in tumor/cancer therapy. Furthermore, biologically active complexes have garnered extensive attention as inclusions in the design of potential antitumor agents [17]. Also, dithiocarbamate ligands are known to be medically beneficial, and are utilized as radio target in the chemotherapy of tumors [18,19].

Therefore, this research aims to characterize the synthesized Mn (II) arginine dithiocarbamate complex and examine the compound's anticancer activity against MCF-7 cell line, and the analysis outcomes were determinants of the compound's anticancer efficacy.

METHODS

Materials

CS₂ 99.5% (Ajax Chemical Ltd), Cisplatin, Roswell Park Memorial Institute Medium, DMSO, Manganese(II)sulphate, cysteine PA, 95% Ethanol, 95% methanol, 95% Acetone, 95% n-hexane, and 95% Acetonitrile (Central Laboratory of Hasanuddin University, Indonesia). MCF-7 were tested at Padjadjaran University.

Synthesis of Mn (II) Complex Compounds with arginine dithiocarbamate ligand

A mass of 0.5095g MnSO₄.H₂O (3mmol) was placed in an Erlenmeyer glass, and made into a solution with 10 mL of ethyl alcohol (solution 1), accompanied by 0.9001g (5mmol) of Arginine, and a subsequent dissolution with 10 mL of ethanol. Then, 0.302 mL (5mmol) CS₂ solution was added to solution 1 slowly at cold temperature, and combined with a magnetic stirrer for 30 minutes (solution 2). Additionally, the resulting precipitate

was filtered and placed in a desiccator to facilitate dehydration, and then crystallized with a solvent prepared from an acetonitrile and ethanol blend (1: 2, v / v), to obtain pure crystals to be further analyzed and characterized.

Characterization of Mn (II) Arginine dithiocarbamate Complexes

The ligands were physically characterized by the implementation of melting point and conductivity tests, as well as chemically by UV-Vis and FT-IR spectrophotometric assays.

Cytotoxicity Test against Cancer Cell Lines

The sample solutions of the complexes at various concentrations, alongside cisplatin ($IC_{50} = 5.7 \mu\text{g} / \text{mL}$) used as a positive control were added to the MCF-7 cells and subsequently incubated for 24 hours. Then, the resulting mixture was added to the dye reagent and re-incubated for another 4 hours at 37 °C. Consequently, the number of HeLa cells inhibited by the test sample after uptake was measured by the use of a multimode reader at λ_{maks} (570-600 nm) after the inclusion of stop solution reagents. Furthermore, the IC_{50} values were calculated by the extrapolation of the 50% line produced by the uptake of the positive control on the absorption curve at various sample concentrations.

Preparation of Media, Positive Control and Arginine dithiocarbamate complex

The liquid culture media was prepared at the Roswell Park Memorial Institute Medium (RPMI) by the combination of 10% Fetal Bovine Serum (FBS) and 50 μL /50mL antibiotics, with Cisplatin as the positive control. Meanwhile, the stock was prepared by the dissolution of cysteine dithiocarbamate complex in the nontoxic solvent, DMSO at a series of strengths. Furthermore, the antiproliferation assay work solution used was the Presto Blue™ Cell Viability Reagent.

Preparation of MCF-7 Cells

The MCF-7 cells were confluent at 70%, discharged onto media dish, and doused with 1 mL *Phosphate Buffered Saline* (PBS) two times, followed by 1 ml Trypsin-EDTA solution added into the dish, and then incubated for 5 minutes. Furthermore, the cell layers were dispersed, and appeared to float when viewed with the inverted microscope. Finally, the cells were inserted into a tube containing growth media, rotated at 3000 rpm for 5 minutes, the supernatant subsequently disposed, and the resultant pellets dissolved in a tube

of media.

Seeding cells into 96 well plates

The cell count and viability were performed with trypan blue exclusion, and then resuspended to produce a final density of 170,000 cells/mL in the media. (17,000 cells/well). Meanwhile, 10 μ L of trypan blue was prepared in sterile microtube, 10 μ L of the cell suspension added to the solution and subsequently homogenized. Then, the hemocytometers and the lids were cleaned with the use of 70% ethanol, dried, and 10 μ L of the trypan blue cell solution inserted slowly into one of the chambers with the use of a pipette. Finally, the number of viable cells per mL was determined, the cell cultures seeded into 96 well plates, incubated for 24 hours or until a minimum of 70% confluent cells at 37°C and 5% CO₂ gas were observed.

Cell treatment with positive sample/ positive control/negative control

A total of eight 1.5 mL microtubes were prepared, with each container labeled with the appropriate dilution strength, and the sample stock diluted into eight corresponding concentration variants with the use of a media solvent. Then, 96 well plates containing cells from the incubator were collected and labelled along the left margins according to the rows to be treated by the standard or sample. In addition, the media was discarded from each well. Then, 100 μ L of each sample, along with the cisplatin control in the microtubes were transferred into each of the corresponding wells on the 96 plates containing the cells with the use of a micropipette and subsequently re-incubated for 24 hours.

Provision of Presto Blue reagents and absorbance measurements

A volume of 9 mL of media from each tube was added to 1mL of "Presto Blue™ Cell Viability Reagent" (10 μ L of reagent for 90 μ L media), and then 100 μ L of the resulting mixture inserted into each well. After this, the microplates were incubated for 1-2 hours until discoloration occurred. On entrance into the viable cell, the indicator was transformed from the non-luminous resazurin blue, into the highly fluorescent resorufin counterpart. The converted values were proportionate to the living cell count, and the absorbances were consequently capable of quantitative measurement, as the absorbance spectrum was utilized for resazurin and resorufin. Finally, these values were estimated at a wave length of 570nm (reference: 600nm) using a multimode reader.

RESULTS

The yield of the Mn(II) arginine dithiocarbamate compound synthesized was 28.39%, and the melting point estimated between 202°C – 204°C.

UV-Vis characterization

The complex characterized by UV-Vis spectrophotometers displayed several wavelengths as illustrated in Table 1. Furthermore, the absorption at 385 nm was representative of the transition of electrons from the orbital $n \rightarrow \pi^*$ in the group $N = C = S$. Meanwhile, the wavelength of 246 nm indicated a transition from the orbitals $\pi \rightarrow \pi^*$ in the group CS_2 , attributable to the hyperconjugation effect experienced by the R group. The spectral outcomes of the synthesized ligand are shown in figure 2.

IR characterization

A single bond group ν (C - N) exists in the dithiocarbamate complex at the wave number between 1350-1250 cm^{-1} and ν (C = N) at 1690 - 1640 cm^{-1} . Meanwhile, the C - S bond group occurs at wave numbers 550 – 800 cm^{-1} , and the C = S at 1050-1200 cm^{-1} [11]. Furthermore, the bonds between the metal and the ligands are observable from the far infrared absorption ranging from the wave number 400-100 cm^{-1} , as seen in the linkages formed between sulfur or nitrogen and metals [12].

Also, the metal coordination bonds with ligands are identifiable from the resulting spectrum as observed in Table 2. Subsequently, the interactions between the Mn bond and the S group were detected at wave number 354 cm^{-1} , with the O atom at 445 cm^{-1} and finally, the N atom at 499 cm^{-1} . In addition, the C = N double bond was identified from the spectrum with the wave number 1645 cm^{-1} , while the C = S double bond coordinating with Mn ion was observed at 1116 cm^{-1} . Furthermore, Figure 3 shows the FT-IR spectrum of the complex compound, with each compound having a specific absorption in the infrared spectrum dependent on the metal and ligands.

Cytotoxicity Test on MCF-7 Cells

The IC_{50} value of the complex was determined from the regression equation $y = -0.0016x + 0.6826$ (Figure 4), obtained by replacing the value of y with half the value of the control (DMSO). Subsequently, the well plate documentation results of Mn (II) arginine dithiocarbamate, as well as the comparison of sample concentrations with media + cells, alongside cisplatin for MCF-7 are displayed in Figure 5. Also, the IC_{50} of the sample were

evaluated due to similarities of the color to cisplatin, and the value obtained between 125-250 $\mu\text{g} / \text{mL}$.

The apoptosis of MCF-7 cells against cisplatin and a sample of the complex are illustrated in Figure 6, and this phase was dependent on the concentration and nature of the inhibitory substance. Subsequently, in the concentration of the sample variant from 7.81 to 62.5 $\mu\text{g} / \text{mL}$, no visible cell death was observed, and this phenomenon was capable of associated to the image of the initial cell media that remained normal without treatment. Therefore, apoptosis commenced at the 125 $\mu\text{g}/\text{mL}$ concentration sample, after an addition of cisplatin to the media. Also, the MCF-7 cells experienced late apoptosis at higher concentrations.

Discussion

Metals exhibit distinct features comprising redox activity, several coordination structures, and reactivity towards organic compounds. As a result of this function, these elements typically undergo strict regulations, and abnormal ionic strengths are affiliated with numerous diseases, including cancer [13]. Therefore, metal complexes, either as drugs or prodrugs, have become very promising anticancer candidates [14,20,21]. Also, the use of metals and the corresponding salts for medicinal purposes, from iatrochemistry to contemporary medicine, has existed from time immemorial [21,22]. Consequently, the invention of cisplatin, cis-[Pt (II) (NH₃)₂ Cl₂], was a breakthrough and sparked interests in platinum(II)- and other metallic composites as prospective chemotherapeutic agents [13].

Moreover, transition metals including copper, iron, and manganese, and so on, are linked with many biological processes, including electron transfer and catalysis, as well as fundamental functions, and are therefore regularly involved with the binding sites of biological polypeptides [23,24]. Manganese (Mn) is an essential trace metal indispensable in enzyme functionality, for instance, arginase, glutamine synthetase, and Mn-superoxide dismutase activity [25]. Furthermore, this metal is able to assume various valence forms, and limited data suggest the propensity to undergo oxidative modifications whilst in the body [26,27]. Despite the normal oxidation number of the ion in enzymes being Mn(III), majority of manganese intake from diet and other circumstances are either Mn(II) or Mn(IV) [27]. This metal is principal for the maintenance of the functionality, as well as

biochemical and cellular modulation required by living organisms [28]. Also, the element is vital for growth and development, acts during the activation of immunity, blood glucose control, adenosine triphosphate (ATP) regulation, reproduction, digestion and skeletal growth [28,29].

In addition to tetraethylthiuram disulfide (DSF), diethyldithiocarbamate (DDTC) and pyrrolidine dithiocarbamate (PDTC) also belong to the dithiocarbamate group revealed as powerful metal sequestering agents [13,30–33]. DDTC was revealed to be capable of combining with copper to create a novel potent inhibitory complex of functions similar to proteasomal chymotrypsin, promote cell death, decrease androgen (AR) and estrogen receptor (ER α and ER β) protein manifestation in malignant prostate and breast tissues [13]. Reports garnered further revealed PDTC, after linkage to copper, exhibited comparable activities on cultivated human prostate cancer cells, along with the suppression of proliferation [33]. Also, the anticancer activity of copper has been postulated to reflect in the manganese (II) arginine dithiocarbamate compound.

The cytotoxicity of the synthesized complex was tested in vitro against the MCF-7 cancer cells and compared with cisplatin, the most commonly used drug currently recognized as toxic to these cancer cells. From the results displayed on Table 3, the IC₅₀ value of the Mn (II) complex was similar to the value of cisplatin, and hence, expressed as active against cancer cells. Furthermore, the cytotoxicity results of the complex were more effective against the cells (IC₅₀ = 211.53 $\mu\text{g} / \text{mL}$) when compared to the IC₅₀ value of 632.42 $\mu\text{g} / \text{mL}$ produced by the semi-polar fraction of *Dioscorea esculenta* L. as reported by Haryoto [34].

According to the Prayong classification (2008) [35] regarding the IC₅₀ standard for cytotoxic samples, the Mn (II) complex belongs to the medium cytotoxic category owing as the IC₅₀ value occurred between 100-1000 $\mu\text{g}/\text{mL}$. In addition, the ligand's cytotoxic activities against the cell line are perceivable in terms of the bioactivity of metals in the body, as well as the complex structural properties. Also, the consideration of Mn (II) from the view of HSAB properties included in the category of borderline acids and Nitrogen groups from guanine, the basic framework of DNA included in the category of soft bases, permitted the formation of a strong bond between the complex and two DNA strands in a double helix. Furthermore, the nature of Mn, an essential element with bioactive capacities in the human body, compared to harmful cisplatin, depleted the toxicity. Subsequently, the high IC₅₀ value of the Mn(II) complex was influenced by arginine dithiocarbamate ligands employed in the synthesis of complex compounds, and able to process ligand intercalation

into DNA base pairs. Therefore, the propensity of metal complexes to not only covalently coordinate, but also bond non-covalently was affirmed, and this ion was able to interact with DNA through the formation of intra-strand cross-links [36]. Also, the resulting bonds prevented the mitotic phase of cancer cells, causing these structures to become stiff, deter repair and induce cellular apoptosis.

Mn (II) metal complexes with arginine dithiocarbamate ligand have been successfully synthesized and characterized. And it shows that there has been coordination between the Mn (II) atom with Sulfur (S), Nitrogen (N) and Oxygen (O) from the arginine dithiocarbamate ligand. This complex can inhibit cancer cell proliferation in a way that depends on the concentration of the Mn (II) complex. Its IC₅₀ value indicates that Mn (II) arginine dithiocarbamate has excellent inhibitory activity against MCF-7 cancer cells. In fact, the Mn (II) arginine dithiocarbamate complex can make cancer cells undergo apoptosis in vitro in a concentration-dependent way, which can inhibit the proliferation of MCF-7 cancer cells [9]. Thus, the Mn (II) arginine dithiocarbamate complex could be a potential cancer drug.

The challenge faced in this study is the difficulty of finding a single solvent during the crystallization stage of the Mn complex, as for the solution by using a double solvent, namely acetonitrile and ethanol.

Conclusions

The Mn (II) arginine dithiocarbamate complex synthesis was performed by an in-situ method through an interaction between a primary amine (arginine) and carbon disulfide (CS₂) in ethanol, alongside the Mn metal solvents in the form of salts. In addition, the analysis of the Mn (II) complex against MCF-7 cancer cell line revealed the existence of moderate cytotoxicity with IC₅₀ = 211.53 µg / mL, attesting to activity as opposed to the cell line.

Provenance and peer review

Not commissioned, externally peer reviewed.

References

- [1] A. Adjiri, DNA Mutations May Not Be the Cause of Cancer, *Oncol. Ther.* 5 (2017) 85–101. <https://doi.org/10.1007/s40487-017-0047-1>.

- [2] M.R. Stratton, P.J. Campbell, P.A. Futreal, The cancer genome, *Nature*. 458 (2009) 719–724. <https://doi.org/10.1038/nature07943>.
- [3] J. Ferlay, I. Soerjomataram, M. Ervik, R. Dikshit, S. Eser..., *Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11*. Lyon, France: International Agency for Research on Cancer; 2013, (2015).
- [4] M. of H.R. of Indonesia, *Panduan Program Nasional Gerakan Pencegahan dan Deteksi Dini Kanker Leher Rahim dan Kanker Payudara*, (2015). <http://www.depkes.go.id/article/view/15021800011/situasi%20penyakit%20kanker.html>.
- [5] B.W. Henderson, T.J. Dougherty, HOW DOES PHOTODYNAMIC THERAPY WORK?, *Photochem. Photobiol.* 55 (1992) 145–157. <https://doi.org/10.1111/j.1751-1097.1992.tb04222.x>.
- [6] M.A. Zoroddu, J. Aaseth, G. Crisponi, S. Medici, M. Peana, V.M. Nurchi, The essential metals for humans: a brief overview, *J. Inorg. Biochem.* 195 (2019) 120–129. <https://doi.org/10.1016/j.jinorgbio.2019.03.013>.
- [7] S.M. Morris, Arginine Metabolism Revisited, *J. Nutr.* 146 (2016) 2579S-2586S. <https://doi.org/10.3945/jn.115.226621>.
- [8] A. Royer, M. Ménand, A. Grimault, P.Y. Communal, Development of Automated Headspace Gas Chromatography Determination of Dithiocarbamates in Plant Matrixes, *J. Agric. Food Chem.* 49 (2001) 2152–2158. <https://doi.org/10.1021/jf0013196>.
- [9] L. YANG, J. TAN, B.-C. WANG, L.-C. ZHU, Synthesis, characterization, and anti-cancer activity of emodin-Mn(II) metal complex, *Chin. J. Nat. Med.* 12 (2014) 937–942. [https://doi.org/10.1016/S1875-5364\(14\)60137-0](https://doi.org/10.1016/S1875-5364(14)60137-0).
- [10] E. Sletten, N. ge Frystein, Sequence-Selective Binding of Transition Metal Complexes to DNA, in: N. Hadjiliadis, E. Sletten (Eds.), *Met. Complex–DNA Interact.*, John Wiley & Sons, Ltd, Chichester, UK, 2009: pp. 1–30. <https://doi.org/10.1002/9781444312089.ch1>.
- [11] C. Bernal, E.A. Neves, É.T.G. Cavaleiro, Differences in thermal decomposition of Ag (I), Mn (II), Fe (II) and Fe (III) complexes of cyclic dithiocarbamates, *Thermochim. Acta.* 370 (2001) 49–55.
- [12] B. Wang, H.-Z. Ma, Q.-Z. Shi, Chiral lanthanide(III) complexes of sulphur–nitrogen–oxygen ligand derived from aminothiourea and sodium D-camphor-β-sulfonate, *Inorg. Chem. Commun.* 4 (2001) 409–412. [https://doi.org/https://doi.org/10.1016/S1387-7003\(01\)00223-4](https://doi.org/https://doi.org/10.1016/S1387-7003(01)00223-4).

- [13] M. Frezza, S. Hindo, D. Chen, A. Davenport, S. Schmitt, D. Tomco, Q.P. Dou, Novel metals and metal complexes as platforms for cancer therapy., *Curr. Pharm. Des.* 16 (2010) 1813–1825. <https://doi.org/10.2174/138161210791209009>.
- [14] M. Galanski, Recent developments in the field of anticancer platinum complexes., *Recent Pat. Anticancer. Drug Discov.* 1 (2006) 285–295. <https://doi.org/10.2174/157489206777442287>.
- [15] M. Frezza, S. Schmitt, Q. Ping Dou, Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy, *Curr. Top. Med. Chem.* 11 (2011) 2888–2905. <https://doi.org/10.2174/156802611798281311>.
- [16] D. Buac, S. Schmitt, G. Ventro, F. Rani Kona, Q. Ping Dou, Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells, *Mini-Reviews Med. Chem.* 12 (2012) 1193–1201. <https://doi.org/10.2174/138955712802762040>.
- [17] N. Awang, I. Baba, Diorganotin(IV) Alkylcyclohexyldithiocarbamate Compounds: Synthesis, Characterization and Biological Activities (Sebatian Diorganostanum(IV) Alkilsikloheksilditiokarbamat: Sintesis, Pencirian dan Aktiviti Biologi), in: 2008.
- [18] A. Korde, D. Satpati, A. Mathur, M. Mallia, S. Banerjee, K. Kothari, H.D. Sarma, P. Choudhari, M. Venkatesh, ^{99m}Tc-labeling of colchicine using [^{99m}Tc(CO)₃(H₂O)₃]⁺ and [^{99m}TcN]₂⁺ core for the preparation of potential tumor-targeting agents, *Bioorg. Med. Chem.* 14 (2006) 793–799. <https://doi.org/10.1016/j.bmc.2005.09.006>.
- [19] I. Baba, I. Raya, Praseodymium Dithiocarbamate 1,10 Phenantroline Complexes, *Sains Malaysiana.* 39 (2010) 45–50.
- [20] V. Milacic, D. Fregona, Q.P. Dou, Gold complexes as prospective metal-based anticancer drugs., *Histol. Histopathol.* 23 (2008) 101–108. <https://doi.org/10.14670/HH-23.101>.
- [21] L.R. Kelland, An update on satraplatin: the first orally available platinum anticancer drug, *Expert Opin. Investig. Drugs.* 9 (2000) 1373–1382. <https://doi.org/10.1517/13543784.9.6.1373>.
- [22] D. Wang, S. Lippard, Cellular processing of platinum anticancer drugs, *Nat. Rev. Drug Discov.* 4 (2005) 307–320.
- [23] C. Orvig, M.J. Abrams, Medicinal Inorganic Chemistry: Introduction, *Chem. Rev.* 99 (1999) 2201–2204. <https://doi.org/10.1021/cr980419w>.
- [24] S.S. Hindo, M. Frezza, D. Tomco, M.J. Heeg, L. Hryhorczuk, B.R. McGarvey, Q.P.

- Dou, C.N. Verani, Metals in anticancer therapy: Copper(II) complexes as inhibitors of the 20S proteasome, *Eur. J. Med. Chem.* 44 (2009) 4353–4361. <https://doi.org/https://doi.org/10.1016/j.ejmech.2009.05.019>.
- [25] D.S. Ávila, L.G. Costa, M. Aschner, Manganese, in: M.J. Aminoff, R.B.B.T.-E. of the N.S. (Second E. Daroff (Eds.)), *Encycl. Neurol. Sci.*, Second Edi, Academic Press, Oxford, 2014: pp. 995–997. <https://doi.org/https://doi.org/10.1016/B978-0-12-385157-4.00263-3>.
- [26] M. ŠARIĆ, R. LUCCHINI, Manganese, in: G.F. Nordberg, B.A. Fowler, M. Nordberg, L.T.B.T.-H. on the T. of M. (Third E. Friberg (Eds.)), *Handb. Toxicol. Met.*, Third Edit, Academic Press, Burlington, 2007: pp. 645–674. <https://doi.org/https://doi.org/10.1016/B978-012369413-3/50087-2>.
- [27] R.G. Lucchini, M. Aschner, Yangho kim, M. Šarić, Manganese, in: G.F. Nordberg, B.A. Fowler, M.B.T.-H. on the T. of M. (Fourth E. Nordberg (Eds.)), *Handb. Toxicol. Met.*, Fourth Edi, Academic Press, San Diego, 2015: pp. 975–1011. <https://doi.org/https://doi.org/10.1016/B978-0-444-59453-2.00045-7>.
- [28] D. Milatovic, R.C. Gupta, Z. Yin, S. Zaja-Milatovic, M. Aschner, Manganese, in: R.C.B.T.-R. and D.T. (Second E. Gupta (Ed.)), *Reprod. Dev. Toxicol.*, Second, Academic Press, 2017: pp. 567–581. <https://doi.org/https://doi.org/10.1016/B978-0-12-804239-7.00032-9>.
- [29] D. Milatovic, R.C. Gupta, Z. Yin, S. Zaja-Milatovic, M. Aschner, Manganese, in: R.C.B.T.-R. and D.T. Gupta (Ed.)), *Reprod. Dev. Toxicol.*, First, Academic Press, San Diego, 2011: pp. 439–450. <https://doi.org/https://doi.org/10.1016/B978-0-12-382032-7.10034-7>.
- [30] D. Chen, V. Milacic, M. Frezza, Q.P. Dou, Metal complexes, their cellular targets and potential for cancer therapy., *Curr. Pharm. Des.* 15 (2009) 777–791. <https://doi.org/10.2174/138161209787582183>.
- [31] V. Milacic, D. Chen, L. Giovagnini, A. Diez, D. Fregona, Q.P. Dou, Pyrrolidine dithiocarbamate-zinc(II) and -copper(II) complexes induce apoptosis in tumor cells by inhibiting the proteasomal activity, *Toxicol. Appl. Pharmacol.* 231 (2008) 24–33. <https://doi.org/https://doi.org/10.1016/j.taap.2008.03.009>.
- [32] D. Chen, Q.P. Dou, New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer, *Expert Opin. Ther. Targets.* 12 (2008) 739–748. <https://doi.org/10.1517/14728222.12.6.739>.
- [33] D. Chen, F. Peng, Q.C. Cui, K.G. Daniel, S. Orlu, J. Liu, Q.P. Dou, Inhibition of

- prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis., *Front. Biosci.* 10 (2005) 2932–2939. <https://doi.org/10.2741/1749>.
- [34] H. Haryoto, Cytotoxic Activities of Ethanol Extract, Nonpolar Semipolar, and Polar Fractions of *Dioscorea esculenta* L.) on MCF7 Cancer Cell, *J. Nutraceuticals Herb. Med.* 2 (2019) 12–19.
- [35] P. Prayong, S. Barusrux, N. Weerapreeyakul, Cytotoxic activity screening of some indigenous Thai plants., *Fitoterapia.* 79 (2008) 598–601. <https://doi.org/10.1016/j.fitote.2008.06.007>.
- [36] R.A. Alderden, M.D. Hall, T.W. Hambley, The Discovery and Development of Cisplatin, *J. Chem. Educ.* 83 (2006) 728. <https://doi.org/10.1021/ed083p728>.

TABLE**Table 1. The Wavelength of Mn (II) arginine dithiocarbamate**

Compound	λ Maximum (nm)	Electronic Transition
Mn(II)argininedithiocarbamate	246	$\pi \rightarrow \pi^*$
	385	$n \rightarrow \pi^*$

Table 2. IR data of Mn (II) arginine dithiocarbamate

Compound	$\nu(\text{C}=\text{N})$	$\nu(\text{C}=\text{S})$	$\nu(\text{M}-\text{S})$	$\nu(\text{M}-\text{O})$	$\nu(\text{M}-\text{N})$
Mn(II)ArgDtc	1645 s	1116 m	354 w	445 w	499 w

s = strong; m = medium; w = weak

Table 3. IC₅₀ values of the Mn (II) arginine dithiocarbamate Complexes

Compounds	t (h)	IC ₅₀ (µg/mL)
		MCF-7
Mn(II)ArgDtc	48	211,53
Cisplatin	48	53,48


FIGURE

Figure 1. Synthesis reaction of Mn (II) arginine dithiocarbamate




Figure 2. UV-Vis Spectrum of Mn (II) arginine dithiocarbamate




Figure 3. IR Spectrum of Mn (II) arginine dithiocarbamate




Figure 4. Cytotoxicity Curve of Mn (II) arginine dithiocarbamate for MCF-7 cancer cells




Figure 5. Well Plate Documentation Test Results of Mn(II)arginine dithiocarbamate for MCF-7




Figure 6. Apoptosis of MCF-7 cells induced by Mn (II) arginine dithiocarbamate (arrow)

Author's Response To Reviewer Comments

Close

Dear reviewer,

Thank you for your valuable comment. Our replies to the reviewer's inquiries and revised points are as follows. Please confirm the relevant parts highlighted in yellow in the revised manuscript.

1. Comment 1: Introduction

How widely utilised is Mn(II) in combination with the ligand arginine dithiocarbamate in cancer therapy?

Reply to comment 1:

We have revised the introduction section. This stated on page 2 paragraph 2 and 3.

..... Mn (II) metal is an essential metal which is widely used in the body as a cofactor in several enzymes.... The interaction of the Mn complex with DNA takes place through hydrogen bonds involving hydrogen bonds.

... The dithiocarbamate class of metal complexing compounds has become a new class of proteasome anticancer inhibitors with great potential to overcome the limitations seen with the use of bortezomib...

2. Comment 2: Introduction

Are there any complications or side effects associated with its use?

Reply to comment 2:

We have revised the introduction section. This stated on page 3 paragraph 1.

... Complications from use are not yet known, because this is only stage 1 in vitro research, ...

3. Comment 3: Results and discussion

If would be helpful if the authors included in the discussion/conclusion what the key take away messages of this research are, and what has been learnt.

Reply to comment 3:

We have revised the discussion section. This stated on page 9.

Mn (II) metal complexes with arginine dithiocarbamate ligand have been successfully synthesized and characterized.

4. Comment 4: Results and discussion:

Please discuss the limitations and challenges encountered throughout this study, and how they were effectively overcome.

Reply to comment 4:

We have revised the discussion section. This stated on page 9.

The challenge faced in this study is the difficulty of finding a single solvent during the crystallization stage of the Mn complex, ...

We look forward to hearing from you

Best Regards,
Author

Close



prihantono md <prihantono.md@gmail.com>

Editor handles AMSU-D-20-00466R1

1 message

Annals of Medicine and Surgery <em@editorialmanager.com>

Thu, Nov 5, 2020 at 12:36 AM

Reply-To: Annals of Medicine and Surgery <annalsjournal@elsevier.com>

To: Prihantono Prihantono <prihantono.md@gmail.com>

Ms. Ref. No.: AMSU-D-20-00466R1

Title: Potential Anticancer Activity of Mn (II) Complexes Containing Arginine Dithiocarbamate Ligand on MCF-7 Breast Cancer Cell Lines

Annals of Medicine and Surgery

Dear Dr Prihantono,

Your submission "Potential Anticancer Activity of Mn (II) Complexes Containing Arginine Dithiocarbamate Ligand on MCF-7 Breast Cancer Cell Lines" will be handled by Editor in Chief Riaz Ahmed Agha, BSc, MBBS, MRCSEng, MSc, D.Phil, FRSPH.

You may check on the progress of your paper by logging on to the Editorial Manager as an author.

Thank you for submitting your work to this journal.

Kind regards,

Editorial Manager
Annals of Medicine and Surgery

For further assistance, please visit our customer support site at <http://help.elsevier.com/app/answers/list/p/7923>

Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EM via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/amsu/login.asp?a=r>). Please contact the publication office if you have any questions.



prihantono md <prihantono.md@gmail.com>

Production has begun on your article [AMSU_1929] in Annals of Medicine and Surgery

1 message

A.Achuthan@elsevier.com <A.Achuthan@elsevier.com>

Tue, Nov 10, 2020 at 7:29 PM

To: prihantono.md@gmail.com

Our reference: AMSU 1929
Article reference: AMSU_AMSU-D-20-00466
Article title: Potential Anticancer Activity of Mn (II) Complexes Containing Arginine Dithiocarbamate Ligand on MCF-7 Breast Cancer Cell Lines
To be published in: Annals of Medicine and Surgery

Dear Dr. Prihantono,

Thank you for choosing to publish in Annals of Medicine and Surgery. Please read this e-mail carefully as it contains important information.

FINALIZE PUBLISHING YOUR ARTICLE:

We work hard to publish our authors' articles online as quickly and efficiently as possible, therefore processing of your accepted manuscript for publication has already begun. To ensure that we publish your article in accordance with your wishes, please now complete the forms found here:

<http://authors.elsevier.com/authorforms/AMSU1929/3a25c8196c6233528a4c1f09e0b520f8>

If this link does not work, please copy the entire URL (noting that it may run on to a second line in this message) into your browser. You should log in with your Elsevier Profile credentials, which you may have already created when submitting your article.

CHECK YOUR CONTACT DETAILS:

Please check that your details listed below are correct so we can contact you if needed:

Dr. Prihantono
Hasanuddin University
Department of Surgery
Jalan Perintis Kemerdekaan KM 11
Makassar 90245
Indonesia
Phone: not available
Fax: +62411585984
E-mail: prihantono.md@gmail.com

YOUR REFERENCE NUMBER:

Lastly, to help us provide you with the best service, please make a note of your article's reference number AMSU 1929 and quote it in all of your messages to us.

Thank you for your cooperation.

Kind regards,

A Achuthan
Data Administrator

Elsevier

E-Mail: A.Achuthan@elsevier.com

HAVE QUESTIONS OR NEED ASSISTANCE?

For further assistance, please visit our Customer Support site, where you can search for solutions on a range of topics, such as Open Access or payment queries, and find answers to frequently asked questions. You can also talk to our customer support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email.

Get started here: <http://service.elsevier.com/app/home/supporthub/publishing>

Copyright © 2015 Elsevier B.V. | Privacy Policy <http://www.elsevier.com/privacypolicy>

Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom, Registration No. 1982084



prihantono md <prihantono.md@gmail.com>

Rights and Access form completed for your article [AMSU_1929]

1 message

Elsevier - Author Forms <Article_Status@elsevier.com>

Wed, Nov 11, 2020 at 1:00 AM

To: prihantono.md@gmail.com

ELSEVIER

Dear Dr. Prihantono,


Thank you for completing the Rights and Access Form for your article *Potential Anticancer Activity of Mn (II) Complexes Containing Arginine Dithiocarbamate Ligand on MCF-7 Breast Cancer Cell Lines* on November 10, 2020.

The Order Summary is attached to this email.

Your article will be free for everyone to read online as soon as it is published.

If you have any questions, please do not hesitate to contact us.

To help us assist you, please quote our article reference AMSU1929 in all correspondence.



Now that your article has been accepted, you will want to maximize the impact of your work.

Elsevier facilitates and encourages authors to share their article responsibly. To learn about the many ways in which you can share your article whilst respecting copyright, visit:

www.elsevier.com/sharing-articles.

Kind regards,

Elsevier Researcher Support



Seven strategies for you to create a brand and promote your research

Learn how to give your research the visibility it deserves with these seven strategies.

> [Access module now](#)

Have questions or need assistance?

Please do not reply to this automated message.

For further assistance, please visit our [Elsevier Support Center](#) where you search for solutions on a range of topics and find answers to frequently asked questions.

You can also talk to our researcher support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email.

© 2018 Elsevier Ltd | [Privacy Policy](http://www.elsevier.com/privacypolicy) <http://www.elsevier.com/privacypolicy>

Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom,
Registration No. 1982084. This e-mail has been sent to you from Elsevier Ltd. To ensure delivery to your
inbox (not bulk or junk folders), please add article_status@elsevier.com to your address book or safe
senders list.

2 attachments



Order Confirmation.html

14K



Terms and Conditions of Sale and Purchase.pdf

139K



prihantono md <prihantono.md@gmail.com>

Share your article [AMSU_1929] published in Annals of Medicine and Surgery

1 message

Elsevier - Article Status <Article_Status@elsevier.com>

Fri, Nov 13, 2020 at 3:55 PM

To: prihantono.md@gmail.com

ELSEVIER

Share your article!

Dear Dr. Prihantono,

We are pleased to let you know that the final open access version of your article *Potential Anticancer Activity of Mn (II) Complexes Containing Arginine Dithiocarbamate Ligand on MCF-7 Breast Cancer Cell Lines* is now available online, containing full bibliographic details.

The URL below is a quick and easy way to share your work with colleagues, co-authors and friends. Anyone clicking on the link will be taken directly to the final version of your article on ScienceDirect.



Your article link:

<https://doi.org/10.1016/j.amsu.2020.11.018>

Click on the icons below to share with your network:



You can also use this link to download a copy of the article for your own archive. It also provides a quick and easy way to share your work with colleagues, co-authors and friends. And you are welcome to add it to your homepage or social media profiles, such as Facebook, Google+, and Twitter. Other ways in which you can use your final article have been determined by your choice of [user license](#).

To find out how else you can share your article visit www.elsevier.com/sharing-articles.

Kind regards,

Elsevier Researcher Support

Increase your article's impact

Our [Get Noticed](#) guide contains a range of practical tips and advice to help you maximize visibility of your article.

Publishing Lab

Do you have ideas on how we can improve the author experience? Sign up for the [Elsevier Publishing Lab](#) and help us develop our publishing innovations!

Have questions or need assistance?

Please do not reply to this automated message.

For further assistance, please visit our [Elsevier Support Center](#) where you search for solutions on a range of topics and find answers to frequently asked questions.

You can also talk to our researcher support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email.

© 2018 Elsevier Ltd | [Privacy Policy](#) <http://www.elsevier.com/privacypolicy>

Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom, Registration No. 1982084. This e-mail has been sent to you from Elsevier Ltd. To ensure delivery to your inbox (not bulk or junk folders), please add article_status@elsevier.com to your address book or safe senders list.



prihantono md <prihantono.md@gmail.com>

Track your article [AMSU_1929] accepted in Annals of Medicine and Surgery

1 message

Elsevier - Article Status <Article_Status@elsevier.com>

Thu, Nov 5, 2020 at 11:05 PM

To: prihantono.md@gmail.com

Please note this is a system generated email from an unmanned mailbox.
If you have any queries we really want to hear from
you via our 24/7 support at <http://help.elsevier.com>

Article title: Potential Anticancer Activity of Mn (II) Complexes Containing Arginine Dithiocarbamate Ligand on MCF-7
Breast Cancer Cell Lines
Reference: AMSU1929
Journal title: Annals of Medicine and Surgery
Corresponding author: Dr Prihantono Prihantono
First author: Dr. Prihantono Prihantono
Dear Dr Prihantono,

Your article Potential Anticancer Activity of Mn (II) Complexes Containing Arginine Dithiocarbamate Ligand on MCF-7
Breast Cancer Cell Lines will be published in Annals of Medicine and Surgery.

To track the status of your article throughout the publication process, please use our article tracking service:

<https://authors.elsevier.com/tracking/article/details.do?aid=1929&jid=AMSU&surname=Prihantono>

For help with article tracking: http://help.elsevier.com/app/answers/detail/a_id/90

Yours sincerely,
Elsevier Author Support

HAVE A QUERY?

We have 24/7 support to answer all of your queries quickly.
<http://help.elsevier.com>

UNRIVALLED dissemination for your work

When your article is published, it is made accessible to more than 15 million monthly unique users of ScienceDirect, ranging from scientists, researchers, healthcare professionals and students. This ensures that your paper reaches the right audience, wherever they may be on the globe, and that your research makes the greatest impact possible.

> Find new research yourself at: www.sciencedirect.com

SENDER INFORMATION

This e-mail has been sent to you from Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom. To ensure delivery to your inbox (not bulk or junk folders), please add Article_Status@elsevier.com to your address book or safe senders list.

PRIVACY POLICY

Please read our privacy policy.

<http://www.elsevier.com/privacypolicy>

[T-12b-20150414]



prihantono md <prihantono.md@gmail.com>

Your Elsevier invoice OAD0000080408

1 message

OElsevierInvoicesNoReply@elsevier.com <OElsevierInvoicesNoReply@elsevier.com>

Wed, Nov 11, 2020 at

1:16 PM

Reply-To: OElsevierInvoicesNoReply@elsevier.com

To: prihantono.md@gmail.com

**ELSEVIER**

Dear Sir/Madam,

Please find your invoice **OAD0000080408** attached to this email.

Transaction Number	Due Date	Currency	Transaction Amount
OAD0000080408	11-DEC-2020	USD	650.09

Can we assist you with anything?

For payment and bank account information please refer to the attached invoice. If you have a question regarding the invoice please follow the link to our [customer support center](#).

Kind regards,

Researcher Support**ELSEVIER** | Research Content Operationswww.elsevier.com

*** This is an automatically generated email, please do not reply ***

This email is for use by the intended recipient and contains information that may be confidential. If you are not the intended recipient, please notify the sender by return email and delete this email from your inbox. Any unauthorized use or distribution of this email, in whole or in part, is strictly prohibited and may be unlawful. Any price quotes contained in this email are merely indicative and will not result in any legally binding or enforceable obligation. Unless explicitly designated as an intended e-contract, this email does not constitute a contract offer, a contract

amendment, or an acceptance of a contract offer.



Invoice_OAD0000080408.pdf

48K



prihantono md <prihantono.md@gmail.com>

Your Submission

1 message

Annals of Medicine and Surgery <em@editorialmanager.com>

Thu, Nov 5, 2020 at 8:32 AM

Reply-To: Annals of Medicine and Surgery <annalsjournal@elsevier.com>

To: Prihantono Prihantono <prihantono.md@gmail.com>

Ms. Ref. No.: AMSU-D-20-00466R1

Title: Potential Anticancer Activity of Mn (II) Complexes Containing Arginine Dithiocarbamate Ligand on MCF-7 Breast Cancer Cell Lines

Annals of Medicine and Surgery

Dear Dr Prihantono,

I am pleased to inform you that your paper "Potential Anticancer Activity of Mn (II) Complexes Containing Arginine Dithiocarbamate Ligand on MCF-7 Breast Cancer Cell Lines" has been accepted for publication in Annals of Medicine and Surgery.

This journal is fully open access; all articles will be immediately and permanently free for everyone to read and download. To provide Open Access, this journal has a publication fee which needs to be met by the authors or their research funders.

In the next few days, you will be receiving information via email to allow you to choose one of the CC license options, providing funding information and a link to our payment system.

<a target="_blank" href=" <http://www.elsevier.com/journals/Annals-of-Medicine-and-Surgery/2049-0801/open-access-journal> "> Learn about publishing Open Access in this journal.

Your manuscript will be published online in raw form 4 days from this acceptance.

Below are comments from the editor and reviewers.

Thank you for submitting your work to Annals of Medicine and Surgery.

Yours sincerely,

Jo Frankland
Editorial Office
Annals of Medicine and Surgery

Have you considered publishing a protocol for your next study? You can now publish your study protocol with IJS Protocols, our pioneering new journal for surgical protocols, visit <http://www.ijsprotocols.com> for more details.

Comments from the editors and reviewers:

For further assistance, please visit our customer support site at <http://help.elsevier.com/app/answers/list/p/7923>. Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EM via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/amsu/login.asp?a=r>). Please contact the publication office if you have any questions.

Terms and Conditions of Sale and Purchase

These Terms and Conditions of Sale and Purchase (“Terms”) set forth the terms and conditions governing the purchase of products and services from Elsevier B.V. and/or its affiliated Elsevier company Elsevier Ltd (“Elsevier”) through its web site at <https://authors.elsevier.com> (“Site”). By submitting an order for such products or services, you agree to be bound by these Purchase Terms.

Address

Elsevier B.V. Radarweg 29, 1043 NX Amsterdam, The Netherlands, registered at the Chamber of Commerce Amsterdam, nr. 33158992

Contract Formation

If you wish to purchase any of the products or services offered on this Site, you must submit a completed order form. You will be required to select your products, services or digital content for purchase and complete your delivery and payment details. Once these have been completed, you will have a further chance to check (and correct if necessary) these details prior to submission of your order, and you should print out this page and a copy of these Terms for your future reference.

If we accept your order, you will be sent a confirmation email giving you an order reference number (“Email Confirmation”). Once we have sent this E-mail Confirmation, you will not be able to amend or cancel your order (subject to any right to cancel as described below).

We may correct any error in any unconfirmed order, marketing literature or other document or information issued by us or placed on this Site without any liability.

Right to Cancel

Save as set out below, consumers in the European Union have the right to cancel the purchase until fourteen (14) days after date of delivery of the product or date the service was purchased by sending written notice of cancellation by email to the Site’s customer service department. A model cancellation form is available below for your use but you are not obliged to use this method of cancellation.

This right of cancellation applies to all products and services offered on the Site except:

(a) audio, video, and software products that have been unsealed from their packaging;

(b) digital content not on a tangible medium (e.g. eBooks) once the item has been downloaded;

(c) newspapers, periodicals and magazines which are not supplied under subscription contracts;

(d) services for which performance has completed; and

(e) offprints, colour figures, print on demand services and other products made or services provided to your specification or clearly bespoke to you.

If you cancel the purchase on this basis, we will reimburse to you all payments received from you, including the costs of delivery (except for the additional costs arising if you choose a type of delivery other than the least expensive type of standard delivery offered by us). We may make a deduction from the reimbursement for loss in value of any goods supplied, if the loss is the result of unnecessary handling by you.

Returns

You must return the goods without undue delay and in any event no later than 14 days from the date of notification of cancellation. We will then make the reimbursement without undue delay, and no later than-

- (a) 14 days after the day we receive back from you any goods supplied, or
- (b) (if earlier) 14 days after the day you provide evidence that you have returned the goods, or
- (c) If there were no (physical) goods supplied, 14 days after the day on which we are informed about your decision to cancel the purchase.

We will make the reimbursement using the same means of payment as you used for the initial transaction, unless you have expressly agreed otherwise; in any event, you will not incur any fees as a result of the reimbursement.

Whether these rights of cancellation apply or not, you will be responsible for and will pay the cost of returning the items to us by the same method as it was delivered. The items will be returned at your risk.

Prices (including taxes and delivery) and Payment

The currency and price of products and services offered on this Site shall be that quoted on the Site on the date you place your order. While we make every effort to ensure that prices quoted on the Site are accurate, if there has been an inadvertent error, the correct price will be stated in the E-mail Confirmation and you will have the opportunity to withdraw from the order at that stage if the correct price is higher than that quoted and you are not happy with that higher price.

All prices are exclusive of the cost of postage, packaging and delivery and any applicable Value Added Tax or other sales tax, which will be separately stated on the Site and/or the Email Confirmation.

If your order is for Gold Open Access publication of your article in a hybrid journal (that publishes both subscription and Gold Open Access content), you acknowledge that open access publication of your article is conditional on the timely payment of the article publication charge (APC) required by the journal. If the APC is not paid within the invoice deadline, we reserve the right to remove the Creative Commons license from the article, and to publish and distribute the article as we see fit, including offering the article for sale on a subscription basis. We will also require you to remove any copies of the article that you have posted on any online platform(s).

Delivery/Performance

Where applicable, products ordered will be delivered to the shipping address stated in your order, subject to any geographical restrictions stated on the Site. However, the time and

method of delivery of products or performance of services will be at our discretion, unless otherwise specified and accepted as part of the order. Time for delivery or performance shall not be of the essence.

If the items delivered to you do not include all of the items that you ordered in any particular order or include incorrect items, you must inform us in writing as soon as possible. In any event, our liability is limited to the price of the items not delivered or the cost of replacing such items.

Consumer Protection

If you are a consumer, your statutory rights as a consumer are not affected by these Purchase Terms, and nothing in these Purchase Terms shall exclude or limit our liability arising by virtue of consumer protection legislation, or our liability for fraud or for death or personal injury caused by our negligence, or any other liability to the extent that we cannot so exclude or limit such liability as a matter of law.

Complaints

If you have any questions, comments or complaints regarding these Purchase Terms or your order, please contact our Customer Services Department which is located at:

Author Support
Elsevier Ltd
The Boulevard
Langford Lane
Kidlington
Oxford
OX5 1GB
United Kingdom

[Contact us](#) via our Support Center

<https://service.elsevier.com>

Phone: +44 1865 84 3577

Model Cancellation Form

To: [Author Support](#)

Subject: Cancellation of order for [article_reference].

Or, when sending this by post:

Author Support
Elsevier Ltd
The Boulevard, Langford Lane
Kidlington
Oxford
OX5 1GB
United Kingdom

Dear Sir, Madam,

I hereby give notice that I cancel my contract [DELETE AS APPLICABLE: [of sale of the

following goods/for the supply of the following service].

Goods/Service:

Ordered on:

Received on:

Name of consumer:

Address of consumer:

Signature of consumer:

Date:

General

In the event of any inconsistency between these Terms and the Terms and Conditions of the Site, these Terms shall prevail.

Last revised: 21st October 2019

Copyright © 2019 Elsevier B.V. All rights reserved. [Privacy Policy](#) [Terms & Conditions](#)
[Help](#)

Date: Nov 04, 2020
To: "Prihantono Prihantono" prihantono.md@gmail.com
From: "Annals of Medicine and Surgery" annalsjournal@elsevier.com
Subject: Your Submission

Ms. Ref. No.: AMSU-D-20-00466R1

Title: Potential Anticancer Activity of Mn (II) Complexes Containing Arginine Dithiocarbamate Ligand on MCF-7 Breast Cancer Cell Lines

Annals of Medicine and Surgery

Dear Dr Prihantono,

I am pleased to inform you that your paper "Potential Anticancer Activity of Mn (II) Complexes Containing Arginine Dithiocarbamate Ligand on MCF-7 Breast Cancer Cell Lines" has been accepted for publication in Annals of Medicine and Surgery.

This journal is fully open access; all articles will be immediately and permanently free for everyone to read and download. To provide Open Access, this journal has a publication fee which needs to be met by the authors or their research funders. In the next few days, you will be receiving information via email to allow you to choose one of the CC license options, providing funding information and a link to our payment system.

[Learn about publishing Open Access in this journal.](#)

Your manuscript will be published online in raw form 4 days from this acceptance.

Below are comments from the editor and reviewers.

Thank you for submitting your work to Annals of Medicine and Surgery.

Yours sincerely,

Jo Frankland
Editorial Office
Annals of Medicine and Surgery

Have you considered publishing a protocol for your next study? You can now publish your study protocol with IJS Protocols, our pioneering new journal for surgical protocols, visit <http://www.ijsprotocols.com> for more details.

Comments from the editors and reviewers:

For further assistance, please visit our customer support site at <http://help.elsevier.com/app/answers/list/p/7923>. Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EM via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/amsu/login.asp?a=r>). Please contact the publication office if you have any questions.